Future microbiology · 2026
Antifungal resistance and Ocimum gratissimum L. essential oil-clotrimazole interactions in clinical Candida isolates from Vietnam.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tuan Dang Anh, Masak Jan
Аннотация
AIMS: To describe Candida species distribution and antifungal susceptibility in a Vietnamese tertiary-hospital collection and to evaluate Ocimum gratissimum L. essential oil (OGEO) as an in-vitro adjunct to clotrimazole.
MATERIALS AND METHODS: We retrospectively analysed 423 clinical Candida isolates collected in 2017-2018. Species identification used routine phenotypic methods/VITEK 2; susceptibility to fluconazole, voriconazole, and amphotericin B followed CLSI M27-A3. OGEO was chemically profiled by GC-MS. Crystal violet assays assessed OGEO inhibition of biofilm formation in 30 C. albicans isolates, and checkerboard assays evaluated OGEO-clotrimazole interactions in 20 species-resolved isolates using FICI.
RESULTS: Species-level identification was available for 212 isolates; C. tropicalis (25.8% of the full cohort) slightly exceeded C. albicans (21.8%), while 49.8% were recorded as Candida spp. Overall fluconazole resistance was 13.7%, with higher resistance in C. tropicalis than C. albicans. OGEO was eugenol-rich (66.7%) and inhibited C. albicans biofilm biomass by 71.2% at 1% and 89.6% at 2% v/v. OGEO-clotrimazole interactions were FICI-defined synergistic in 65%, additive in 30%, indifferent in 5%, and never antagonistic.
CONCLUSION: OGEO showed promising in-vitro anti-biofilm and clotrimazole-potentiating activity, supporting further standardized, species-matched, topical-formulation and safety studies.
MATERIALS AND METHODS: We retrospectively analysed 423 clinical Candida isolates collected in 2017-2018. Species identification used routine phenotypic methods/VITEK 2; susceptibility to fluconazole, voriconazole, and amphotericin B followed CLSI M27-A3. OGEO was chemically profiled by GC-MS. Crystal violet assays assessed OGEO inhibition of biofilm formation in 30 C. albicans isolates, and checkerboard assays evaluated OGEO-clotrimazole interactions in 20 species-resolved isolates using FICI.
RESULTS: Species-level identification was available for 212 isolates; C. tropicalis (25.8% of the full cohort) slightly exceeded C. albicans (21.8%), while 49.8% were recorded as Candida spp. Overall fluconazole resistance was 13.7%, with higher resistance in C. tropicalis than C. albicans. OGEO was eugenol-rich (66.7%) and inhibited C. albicans biofilm biomass by 71.2% at 1% and 89.6% at 2% v/v. OGEO-clotrimazole interactions were FICI-defined synergistic in 65%, additive in 30%, indifferent in 5%, and never antagonistic.
CONCLUSION: OGEO showed promising in-vitro anti-biofilm and clotrimazole-potentiating activity, supporting further standardized, species-matched, topical-formulation and safety studies.